Table 1 Baseline characteristics of AYA and adult cohorts of CML patients.
Variable | AYAs, N = 80a | Adults, N = 97a | p-valueb |
|---|---|---|---|
Age; median years (range) | 33 (19, 39) | 59 (40, 79) | <0.001 |
Sex Male | 40/80 (50%) | 50/97 (52%) | 0.8 |
Spleen size, cm; median (range) | 0.0 (0.0, 25.0) | 0.0 (0.0, 20.0) | 0.016 |
WBC, ×109/l; median (range) | 92 (9, 612) | 59 (3, 500) | 0.019 |
Platelet count, ×109/l; median (range) | 520 (158, 1835) | 369 (86, 1778) | 0.007 |
Hemoglobin, g/l; median (range) | 119 (60, 161) | 125 (14, 170) | 0.033 |
Neutrophiles, ×109/l; median (range) | 98 (6, 514) | 46 (2, 471) | 0.026 |
Lymphocytes, %; median (range) | 5.5 (0.0, 23.0) | 7.0 (0.0, 31.0) | 0.2 |
Monocytes, %; median (range) | 2.00 (0.00, 9.00) | 2.00 (0.00, 14.00) | 0.051 |
Basophils, %; median (range) | 5.0 (0.0, 24.0) | 4.0 (0.0, 34.0) | 0.3 |
Blasts, %; median (range) | 1.00 (0.00, 9.00) | 1.00 (0.00, 16.00) | 0.078 |
Eosinophils, %; median (range) | 2.50 (0.00, 11.00) | 2.00 (0.00, 11.00) | 0.2 |
SOKAL | 0.006 | ||
Low | 48/79 (61%) | 37/96 (39%) | |
Intermediate | 17/79 (22%) | 41/96 (43%) | |
High | 14/79 (18%) | 18/96 (19%) | |
EUTOS | 0.2 | ||
Low | 64/79 (81%) | 85 / 96 (89%) | |
Intermediate | 0/79 (0%) | 0 / 96 (0%) | |
High | 15/79 (19%) | 11 / 96 (11%) | |
ELTS | 0.3 | ||
Low | 61/79 (77%) | 64/96 (67%) | |
Intermediate | 11/79 (14%) | 22/96 (23%) | |
High | 7/79 (8.9%) | 10/96 (10%) | |
ACAs | 3/80 (3.8%) | 3/97 (3.1%) | >0.9 |
1st-line TKI | <0.001 | ||
Imatinib | 61/80 (76%) | 94/97 (97%) | |
Nilotinib | 19/80 (24%) | 3/97 (3.1%) |
